Volume : 12, Issue : 06, June – 2025
Title:
REVIEW AND EVALUATION OF REGULATORY PROCESS IN NOT OF STANDARD QUALITY AND SPURIOUS DRUGS IN INDIA IN COMPARISON WITH EUROPE AND USA
Authors :
Guntupalli Sai Durga*, G.Ramakrishna, M.V.Nagabhushanam
Abstract :
The presence of Not of Standard Quality (NSQ) and spurious drugs poses a critical public health threat globally. Developing countries like India are particularly vulnerable due to complex distribution channels and gaps in regulatory enforcement. This review evaluates the regulatory frameworks addressing NSQ and spurious drugs in India and compares them with practices in Europe and the USA. The article highlights regulatory strengths, challenges, and best practices, aiming to propose harmonized strategies to combat the circulation of substandard and counterfeit drugs effectively.
Keywords: Not of Standard Quality (NSQ), Spurious drugs, Public health, India, Europe and the USA.
Cite This Article:
Please cite this article in press Guntupalli Sai Durga et al., Review And Evaluation Of Regulatory Process In Not Of Standard Quality And Spurious Drugs In India In Comparison With Europe And USA., Indo Am. J. P. Sci, 2025; 12(07).
Number of Downloads : 10
References:
1.Khan AN, Khar RK. Current scenario of spurious and substandard medicines in India: a systematic review. Indian J Pharm Sci [Internet]. 2015;77(1):2–7. Available from: https://pubmed.ncbi.nlm.nih.gov/25767312
2. Praveen KG, Ravi SA. A Study on Spurious and Not of Standard Quality Drugs in the State of Andhra Pradesh. African J Pharm Pharmacol. 2018;12(10):130–5.
3. Khan AN, Khar RK. Current scenario of spurious and substandard medicines in india: A systematic review. Indian J Pharm Sci. 2015;77(1):2–7.
4. N K, A J. Regulatory Approach to Ensure Quality of Products – An Indian Perspective of Missing Linkage. Pharm Regul Aff Open Access. 2016;05(01):1–5.
5. Khalid M, and Shivkumar H., “Global Perspective of Regulatory Systems to Spurious, Adullterated and not of Standard Quality Drugs and to recommend measures for their effective eradication in the Indian Regulatory System, Pharma Times, 2018, Vol. 50 No. 12. (March 2018):96–7.
6. Manivannan E, Sivasankari V. Spurious drugs: do we neglect during our clinical practice? a systematic review. Int J Basic Clin Pharmacol. 2016;5(6):2308–10.
7. Iram F. “Contemporary Scenario of SSFFC Medicines: A Systematic Review.” Mod Appl Pharm Pharmacol. 2018;1(4):1–13.
8. Ghanem N. Substandard and falsified medicines: Global and local efforts to address a growing problem. Clin Pharm. 2019;11(5):1–12.
9. Kelesidis T, Falagas ME. Substandard/counterfeit antimicrobial drugs. Clin Microbiol Rev. 2015;28(2):443–64.
10. Kon SG, Mikov M. [Counterfeit drugs as a gobal threat to health]. Med Pregl. 2011;64(5–6):285–90.
11. Nayyar GML, Breman JG, Mackey TK, Clark JP, Hajjou M, Littrell M, et al. Falsified and substandard drugs: Stopping the pandemic. Am J Trop Med Hyg. 2019;100(5):1058–65.
12.Brahmaiah Bonthagarala, Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic Goods Administration, International Journal of Advanced Scientific and Technical Research, ISSN 2249-9954, Issue 6 volume 6, November-December 2016, 144-157.
13.Brahmaiah Bonthagarala, Comparison of Regulatory Requirements for Generic Drugs Dossier Submission in United States and Canada, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 1-
14.Brahmaiah Bonthagarala, Regulatory process and ethics for clinical trials in India (CDSCO)- A Review, The Pharma Innovation Journal, ISSN (E): 2277- 7695 , ISSN (P):2349-8242,2017; 6(4): 165-169.
15.Brahmaiah Bonthagarala, Evaluation of Pharmaceutical Regulatory Systems & Present Scenario of Indian Pharmaceutical Industry, World Journal of Pharmaceutical Research, ISSN 2277–7105, 2017, Volume 6, Issue 5, 368-379.
16. Gautam CS, Utreja A, Singal GL. Spurious and counterfeit drugs: A growing industry in the developing world. Postgrad Med J. 2009;85(1003):251–6.